{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:02:44Z","timestamp":1793689364933,"version":"4.5.1"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,5,6]],"date-time":"2018-05-06T00:00:00Z","timestamp":1525564800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,5,6]],"date-time":"2018-05-06T00:00:00Z","timestamp":1525564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BIAL - Portela & Ca, S.A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1111\/ane.12950","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T05:00:42Z","timestamp":1525669242000},"page":"203-211","source":"Crossref","is-referenced-by-count":10,"title":["Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate"],"prefix":"10.1155","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6681-7134","authenticated-orcid":false,"given":"B. E.","family":"Gidal","sequence":"first","affiliation":[{"name":"School of Pharmacy; University of Wisconsin-Madison; Madison WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Department of Neurology; Lewis Katz School of Medicine; Temple University; Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ben-Menachem","sequence":"additional","affiliation":[{"name":"Sahlgrenska Academy; G\u00f6teborg University; G\u00f6teborg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Carre\u00f1o","sequence":"additional","affiliation":[{"name":"Epilepsy Unit, Hospital Cl\u00ednic; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Blum","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals Inc.; Marlborough MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Soares-da-Silva","sequence":"additional","affiliation":[{"name":"BIAL - Portela & C , S.A.; S. Mamede do Coronado Portugal"},{"name":"Faculty of Medicine; Department of Pharmacology & Therapeutics; University of Porto; Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Falc\u00e3o","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy; Laboratory of Pharmacology; University of Coimbra; Coimbra Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rocha","sequence":"additional","affiliation":[{"name":"BIAL - Portela & C , S.A.; S. Mamede do Coronado Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Moreira","sequence":"additional","affiliation":[{"name":"BIAL - Portela & C , S.A.; S. Mamede do Coronado Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Grinnell","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals Inc.; Marlborough MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Cognigen Corporation; a Simulations Plus company; Buffalo NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fiedler-Kelly","sequence":"additional","affiliation":[{"name":"Cognigen Corporation; a Simulations Plus company; Buffalo NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Passarell","sequence":"additional","affiliation":[{"name":"Cognigen Corporation; a Simulations Plus company; Buffalo NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sunkaraneni","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals Inc.; Marlborough MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,6]]},"reference":[{"key":"10.1111\/ane.12950-BIB0001|ane12950-cit-0001","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/WCO.0b013e328350ba68","article-title":"Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults","volume":"25","author":"Stephen","year":"2012","journal-title":"Curr Opin Neurol"},{"key":"10.1111\/ane.12950-BIB0002|ane12950-cit-0002","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12950-BIB0003|ane12950-cit-0003","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/9781444316667.ch38","volume-title":"The treatment of epilepsy","author":"Almeida","year":"2009","edition":"3"},{"key":"10.1111\/ane.12950-BIB0004|ane12950-cit-0004","first-page":"103","article-title":"Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures","volume":"6","author":"Brown","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/ane.12950-BIB0005|ane12950-cit-0005","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Development of new antiepileptic drugs: challenges, incentives, and recent advances","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12950-BIB0006|ane12950-cit-0006","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-007-0414-1","article-title":"Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment","volume":"64","author":"Almeida","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/ane.12950-BIB0007|ane12950-cit-0007","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1528-1167.2012.03595.x","article-title":"Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers","volume":"54","author":"Nunes","year":"2013","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12950-BIB0008|ane12950-cit-0008","unstructured":"Aptiom \u00ae (Eslicarbazepine Acetate), Full Prescribing Information 2017 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/lael\/2015\/022416s001lbl.pdf"},{"key":"10.1111\/ane.12950-BIB0009|ane12950-cit-0009","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuropharm.2014.09.008","article-title":"Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide","volume":"89","author":"Hebeisen","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1111\/ane.12950-BIB0010|ane12950-cit-0010","doi-asserted-by":"crossref","first-page":"E503","DOI":"10.1208\/aapsj070351","article-title":"Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications","volume":"7","author":"Bhattaram","year":"2005","journal-title":"AAPS J"},{"key":"10.1111\/ane.12950-BIB0011|ane12950-cit-0011","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2165\/11593210-000000000-00000","article-title":"Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008","volume":"50","author":"Lee","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/ane.12950-BIB0012|ane12950-cit-0012","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10928-005-0074-7","article-title":"How modeling and simulation have enhanced decision making in new drug development","volume":"32","author":"Miller","year":"2005","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1111\/ane.12950-BIB0013|ane12950-cit-0013","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/11596290-000000000-00000","article-title":"Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses","volume":"26","author":"Falcao","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1111\/ane.12950-BIB0014|ane12950-cit-0014","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12950-BIB0015|ane12950-cit-0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12950-BIB0016|ane12950-cit-0016","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/epi.12894","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12950-BIB0017|ane12950-cit-0017","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12950-BIB0018|ane12950-cit-0018","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CPP46119","article-title":"Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate","volume":"46","author":"Maia","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1111\/ane.12950-BIB0019|ane12950-cit-0019","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.yebeh.2017.04.019","article-title":"Adjunctive eslicarbazepine acetate: a pooled analysis of three phase III trials","volume":"72","author":"Biton","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1111\/ane.12950-BIB0020|ane12950-cit-0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1600-0404.2009.01233.x","article-title":"Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects","volume":"121","author":"Almeida","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12950-BIB0021|ane12950-cit-0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2017.10.021","article-title":"Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: an integrated analysis of three randomized placebo-controlled trials","volume":"139","author":"Krauss","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12950-BIB0022|ane12950-cit-0022","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11584860-000000000-00000","article-title":"Pharmacotherapy of epilepsy: newly approved and developmental agents","volume":"25","author":"Stephen","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1111\/ane.12950-BIB0023|ane12950-cit-0023","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ane.12645","article-title":"Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study","volume":"153","author":"Schmid","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12950-BIB0024|ane12950-cit-0024","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/epi.14014","article-title":"Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine","volume":"59","author":"Pazdera","year":"2018","journal-title":"Epilepsia"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12950","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12950\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:51:27Z","timestamp":1671540687000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,6]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12950","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5,6]]}}}